Skip to main content
Fig. 9 | Journal of Translational Medicine

Fig. 9

From: Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma

Fig. 9

SFN could be the potential target in the treatment of HCC. A SFN expression level in pan-cancer. B–D SFN was significantly highly expressed in HCC samples than that of the normal samples based on (B) TCGA database, (C) GSE112790 cohort, and (D) GSE76427 cohort. E SFN expression was associated with the TNM stage of patients with HCC, and HCC patients with T1 had better survival than those patients with T2, T3, and T4. F The relative expression of SFN in seven HCC cell lines at mRNA level. G The relative expression of SFN in seven HCC cell lines at the protein level. H Knockdown efficiency of SFN in Huh7 cell line. I Knockdown efficiency of SFN in Sk-Hep-1 cell line. J Knockdown of SFN could significantly inhibit cell proliferation in the Huh7 cell line and Sk-Hep-1 cell line. K, L Downregulation of SFN in Huh7 and SK-Hep-1 cell lines inhibited cell invasion and migration. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page